Sadatoshi Sugae
Overview
Explore the profile of Sadatoshi Sugae including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
252
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamada M, Chishima T, Ishikawa T, Narui K, Sugae S, Tonellato P, et al.
BMC Cancer
. 2025 Feb;
25(1):206.
PMID: 39910468
Background: Each breast cancer (BC) risk factor has different effects on different populations. However, there are no well-studied and validated BC risk prediction models for Japanese women. We developed accessible...
2.
Kida K, Yamada A, Shimada K, Narui K, Sugae S, Shimizu D, et al.
Breast Cancer
. 2024 Mar;
31(3):409-416.
PMID: 38453739
Methods: Patients with histologically confirmed breast cancer who were scheduled to receive standard weekly paclitaxel (80 mg/m) or tri-weekly nab-paclitaxel (260 mg/m) at institutions in our multicenter group were eligible...
3.
Suzuki C, Yamada A, Kawashima K, Sasamoto M, Fujiwara Y, Adachi S, et al.
World J Oncol
. 2023 Nov;
14(6):551-557.
PMID: 38022398
Background: With a prevalence of only 1% among all breast cancers in Japan, apocrine carcinoma (AC) is a rare type of breast cancer, and its clinicopathological characteristics remain unclear. The...
4.
Suzuki C, Yamada A, Adachi S, Shima H, Kida K, Oshi M, et al.
Anticancer Res
. 2021 Jul;
41(7):3597-3606.
PMID: 34230156
Aim: To evaluate the association between bromodomain-containing protein 4 (BRD4) expression and clinicopathological factors and prognosis in human breast cancer specimens. Patients And Methods: We used tissue microarrays constructed from...
5.
Yamamoto S, Chishima T, Sugae S, Yamagishi S, Yamada A, Narui K, et al.
Asian J Surg
. 2021 Apr;
45(1):131-136.
PMID: 33879361
Background: Evaluation of the cosmetic outcome after breast-conserving surgery (BCS) differs depending on the evaluator. We performed a clinical trial to examine the differences between assessments of cosmetic outcomes performed...
6.
Yamamoto S, Narui K, Ishikawa T, Adachi S, Shimada K, Shimizu D, et al.
Anticancer Res
. 2021 Mar;
41(3):1671-1676.
PMID: 33788764
Background/aim: This study aimed to investigate the efficacy of first-line gemcitabine monotherapy for metastatic breast cancer (MBC) and its effect on health-related quality of life (HRQoL) compared with treatment of...
7.
Mikami Y, Yamada A, Suzuki C, Adachi S, Harada F, Yamamoto S, et al.
J Surg Res
. 2021 Mar;
264:45-50.
PMID: 33752166
Background: Sentinel lymph node (SLN) biopsy has been the standard modality for breast cancer patients with clinically node negative disease. In patients who undergo axillary lymph node dissection (ALND) due...
8.
Ishikawa T, Sakamaki K, Narui K, Nishimura H, Sangai T, Tamaki K, et al.
Breast
. 2021 Feb;
56:70-77.
PMID: 33631458
Background: As Asians are more vulnerable to febrile neutropenia (FN) than Caucasians, evaluations of FN incidence and risk factors in Asians are important for the appropriate use of primary pegfilgrastim...
9.
Kawate T, Yoshida A, Sugae S, Asaga S, Kaise H, Saji S, et al.
Breast Cancer
. 2021 Feb;
28(2):247-253.
PMID: 33609229
The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 remains a major global crisis and continues to spread relentlessly around the world. In Japan, the...
10.
Narui K, Ishikawa T, Oba M, Hasegawa Y, Kaise H, Kawate T, et al.
Surg Oncol
. 2020 Oct;
35:447-452.
PMID: 33045629
Background: Pathological complete response (pCR) is often achieved by neoadjuvant chemotherapy (NAC), particularly in hormone receptor-negative breast cancer. Contrast-enhanced magnetic resonance imaging (cMRI) is the most reliable imaging modality to...